{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes",
"headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-12",
"dateModified": "2025-03-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-1 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072461",
"about": {
"@type": "MedicalCondition",
"name": "Famille-1 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.100"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1",
"alternateName": "Cytochrome P-450 CYP1B1",
"code": {
"@type": "MedicalCode",
"code": "D065633",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Purnima Singh",
"url": "https://questionsmedicales.fr/author/Purnima%20Singh",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Shubha Ranjan Dutta",
"url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Chi Young Song",
"url": "https://questionsmedicales.fr/author/Chi%20Young%20Song",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Frank J Gonzalez",
"url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)."
}
},
{
"@type": "Person",
"name": "Kafait U Malik",
"url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interactions between ultrasonographic cervical length and placenta accreta spectrum on severe postpartum hemorrhage in women with placenta previa.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36572390",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijgo.14641"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36120450",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2022.921220"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.",
"datePublished": "2022-09-07",
"url": "https://questionsmedicales.fr/article/36075058",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/AOG.0000000000004923"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serotonin system in the human placenta - the knowns and unknowns.",
"datePublished": "2022-12-01",
"url": "https://questionsmedicales.fr/article/36531448",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2022.1061317"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research progress on N6-methyladenosine in the human placenta.",
"datePublished": "2022-05-25",
"url": "https://questionsmedicales.fr/article/35606944",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1515/jpm-2021-0665"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-1 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Cytochrome P-450 CYP1B1",
"item": "https://questionsmedicales.fr/mesh/D065633"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cytochrome P-450 CYP1B1",
"description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cytochrome P-450 CYP1B1",
"description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cytochrome P-450 CYP1B1",
"description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cytochrome P-450 CYP1B1",
"description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cytochrome P-450 CYP1B1",
"description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1",
"description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Placenta&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de CYP1B1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer CYP1B1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec CYP1B1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Le diagnostic de CYP1B1 est-il complexe ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une mutation de CYP1B1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation."
}
},
{
"@type": "Question",
"name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à CYP1B1 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à CYP1B1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le dépistage génétique et l'éducation sur les risques."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il CYP1B1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1."
}
},
{
"@type": "Question",
"name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important pour CYP1B1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les complications."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles liés à CYP1B1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs pour CYP1B1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon la gravité de la condition."
}
},
{
"@type": "Question",
"name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CYP1B1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être graves et nécessiter une intervention médicale."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CYP1B1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles avec un suivi approprié."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme avec CYP1B1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour CYP1B1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle CYP1B1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il les risques liés à CYP1B1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1."
}
},
{
"@type": "Question",
"name": "L'alimentation a-t-elle un impact sur CYP1B1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme."
}
}
]
}
]
}
To explore the interactions between cervical length (CL) and placenta accreta spectrum (PAS) on severe postpartum hemorrhage (SPPH) in patients with placenta previa....
A retrospective case-control study was conducted at four medical centers in China, and 588 patients with placenta previa were included. The logistic regression analysis and restricted cubic splines (R...
After adjusting for potential confounders, the negative linear dose-response relationship was confirmed by RCS, and the change of odds ratio (OR) was more significant when CL was 2.5 cm or less. The r...
If CL was routinely performed during PAS evaluation, the increased OR of short CL and PAS could allow better patient preparation through counseling....
To investigate the risk of preterm birth in women with a placenta previa or a low-lying placenta for different cut-offs of gestational age and to evaluate preventive interventions....
MEDLINE, EMBASE, CENTRAL, Web of Science, WHO-ICTRP and clinicaltrials.gov were searched until December 2021. Randomized controlled trials, cohort studies and case-control studies assessing preterm bi...
In total, 34 studies were included, 24 reporting on preterm birth and 9 on preventive interventions. The pooled proportions were 46% (95% CI [39 - 53%]), 17% (95% CI [11 - 25%]), 10% (95% CI [7 - 13%]...
Both women with a placenta previa and a low-lying placenta have an increased risk of preterm birth. This increased risk is consistent across all severities of preterm birth between 28-37 weeks of gest...
PROSPERO https://www.crd.york.ac.uk/prospero/, identifier CRD42019123675....
To evaluate whether there are differences in risk factors and maternal outcomes of pregnancies complicated by placenta accreta spectrum depending on the presence or absence of placenta previa....
We performed a systematic search in Medline, EMBASE, ClinicalTrials.gov , and Web of Science from inception through April 25, 2022, without language or date restrictions. Search strategy included the ...
Of the 1,122 articles screened, seven studies were included in the final review. Studies were included if they compared the risk factors and maternal outcomes of pregnancies complicated by placenta ac...
A random-effects model was used to pool the mean differences or odds ratios (OR) and the corresponding 95% CIs using RevMan software. A total of 3,342 pregnancies complicated by placenta accreta spect...
Pregnancies complicated by placenta accreta spectrum without previa had a more prominent association with IVF and prior D&C and myomectomy but were much less likely to be associated with prior cesarea...
PROSPERO, CRD42022307637....
The biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) is a chemical messenger widely distributed in the brain and various other organs. Its homeostasis is maintained by the coordinated activity...
N6-methyladenosine (m6A) is one of the most common epigenetic modifications of eukaryotic RNA. Under the jointly reversible regulation of related enzymes, m6A regulates many aspects of RNA, such as tr...
Data were compiled from 2018 to 2021 citations in PubMed and Google Scholar using the keywords: placenta AND N6-methyladenosine. Seven studies were included....
In this study, we introduced some conventional methods to detect m6A modification at the whole RNA, region (peak) and single base levels. We also summarized the current studies of m6A modification in ...
Although the relevant reports are still in the preliminary stage and some results are inconsistent, studies on methylation m6A modification have contributed new ideas for the research of reproductive ...
Cytochrome P450 aromatase (AROM) and steroid (estrone (E1)/dehydroepiandrosterone (DHEA)) sulfatase (STS) are the two key enzymes responsible for the biosynthesis of estrogens in human, and maintenanc...
Placenta accreta spectrum (PAS) is one of the major causes of maternal morbidity and mortality worldwide with increasing incidence. PAS refers to a group of pathological conditions ranging from the ab...
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has been implicated in the clinical pathology of multiple organs and organ systems....
Describe the current practice of Canadian obstetricians-gynaecologists in managing placenta accreta spectrum (PAS) disorders from suspicion of diagnosis to delivery planning and explore the impact of ...
We distributed a cross-sectional bilingual electronic survey to Canadian obstetricians-gynaecologists in March-April 2021. Demographic data and information on screening, diagnosis, and management were...
We received 142 responses. Almost 60% of respondents said they had read the latest Society of Obstetricians and Gynaecologists of Canada clinical practice guideline on PAS disorders, published in July...
This study demonstrates the impact of the Society of Obstetricians and Gynaecologists of Canada's PAS clinical practice guideline on management choices made by Canadian clinicians. Our study highlight...
Our earlier work has shown that genomic risk for schizophrenia converges with early life complications in affecting risk for the disorder and sex-biased neurodevelopmental trajectories. Here, we ident...